Pharmaceuticals · JUBLPHAR
Pharma - API & CRAMS
from 965 today
We tweak our estimates on Jubilant Pharmova and our FY28E EPS is down by 1.7%. Based on our revised estimates, we retain BUY with a PT of Rs. 1,327.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
